Identification

Name
Dapsone
Accession Number
DB00250  (APRD00345)
Type
Small Molecule
Groups
Approved, Investigational
Description

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)

Structure
Thumb
Synonyms
  • 1,1'-Sulfonylbis(4-aminobenzene)
  • 1,1'-Sulfonylbis[4-aminobenzene]
  • 4-(4-amino-Benzenesulfonyl)-phenylamine
  • 4-(4-Aminophenylsulfonyl)aniline
  • 4-(4-Aminophenylsulfonyl)benzenamine
  • 4-Aminophenyl sulfone
  • 4,4'-Dapsone
  • 4,4'-Diaminodiphenyl sulfone
  • 4,4'-Diaminodiphenyl sulphone
  • 4,4'-Diaminodiphenylsulfone
  • 4,4'-Sulfonylbisaniline
  • 4,4'-Sulfonylbisbenzenamine
  • 4,4'-Sulfonylbisbenzeneamine
  • 4,4'-Sulfonyldianilin
  • 4,4'-sulfonyldianiline
  • Bis(4-aminophenyl)sulfone
  • Bis(P-aminophenyl) sulfone
  • DADPS
  • Dapsona
  • DAPSONE
  • Dapsonum
  • DDS
  • DIAPHENYLSULFONE
  • P-Aminophenyl sulfone
  • P,P-Sulphonylbisbenzamine
  • P,P-Sulphonylbisbenzenamine
  • P,P'-diaminodiphenyl sulfone
External IDs
J04BA02 / NSC-6091
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AczoneGel50 mg/gTopicalAllergan2009-06-24Not applicableUs
AczoneGel5 %TopicalValeant Canada Lp Valeant Canada S.E.C.2011-10-21Not applicableCanada
ACZONE (dapsone) Gel, 7.5%Gel75 mg/gTopicalAllergan2016-02-26Not applicableUs
Avlosulfon Tab 100mgTablet100 mgOralAyerst Laboratories1971-12-311996-09-10Canada
DapsoneTablet100 mgOralJacobus Pharmaceutical1994-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DapsoneTablet100 mg/1OralRemedy Repack2010-11-182016-10-13Us
DapsoneTablet100 mg/1OralAlvogen, Inc.2016-06-13Not applicableUs
DapsoneTablet100 mg/1OralDepartment Of State Health Services, Pharmacy Branch2008-08-15Not applicableUs
DapsoneTablet25 mg/1OralVirtus Pharmaceuticals2016-06-01Not applicableUs
DapsoneTablet25 mg/1OralAlvogen, Inc.2016-06-13Not applicableUs
DapsoneTablet25 mg/1OralPhysicians Total Care, Inc.2009-04-22Not applicableUs
DapsoneTablet100 mg/1OralSeton Pharmaceuticals2016-03-10Not applicableUs
DapsoneTablet100 mg/1OralAv Kare, Inc.2017-05-17Not applicableUs
DapsoneTablet100 mg/1OralJacobus Pharmaceutical1979-07-03Not applicableUs49938 0101 30 nlmimage10 24471218
DapsoneTablet25 mg/1OralGolden State Medical Supply2016-05-09Not applicableUs
Categories
UNII
8W5C518302
CAS number
80-08-0
Weight
Average: 248.301
Monoisotopic: 248.061948328
Chemical Formula
C12H12N2O2S
InChI Key
MQJKPEGWNLWLTK-UHFFFAOYSA-N
InChI
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
IUPAC Name
4-(4-aminobenzenesulfonyl)aniline
SMILES
NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1

Pharmacology

Indication

For the treatment and management of leprosy and dermatitis herpetiformis.

Structured Indications
Pharmacodynamics

Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.

Mechanism of action

Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.

TargetActionsOrganism
AInactive dihydropteroate synthase 2
inhibitor
Mycobacterium leprae (strain TN)
ADihydropteroate synthase 1
inhibitor
Mycobacterium leprae (strain TN)
Absorption

Bioavailability is 70 to 80% following oral administration.

Volume of distribution
Not Available
Protein binding

70 to 90%

Metabolism

Hepatic, mostly CYP2E1-mediated.

Route of elimination

Renal

Half life

28 hours (range 10-50 hours)

Clearance
Not Available
Toxicity

Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.

Affected organisms
  • Mycobacteria
  • Mycobacterium leprae
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredRisk of mild hemolysis and hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredRisk of mild hemolysis and hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when 5'-Deoxy-5'-Methylthioadenosine is combined with Dapsone.Experimental
AbirateroneThe serum concentration of Dapsone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Dapsone.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Dapsone.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Dapsone is combined with Acetaminophen.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Dapsone.Approved, Vet Approved
AmiodaroneThe metabolism of Dapsone can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe risk or severity of adverse effects can be increased when Amodiaquine is combined with Dapsone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Dapsone is combined with Amyl Nitrite.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Dapsone is combined with Antipyrine.Approved
AprepitantThe serum concentration of Dapsone can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Dapsone can be decreased when combined with Armodafinil.Approved, Investigational
ArtemisininThe risk or severity of adverse effects can be increased when Artemisinin is combined with Dapsone.Investigational
ArtemotilThe risk or severity of adverse effects can be increased when Artemotil is combined with Dapsone.Experimental
ArtenimolThe risk or severity of adverse effects can be increased when Artenimol is combined with Dapsone.Approved
ArtesunateThe risk or severity of adverse effects can be increased when Artesunate is combined with Dapsone.Approved
AtazanavirThe metabolism of Dapsone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dapsone can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dapsone.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dapsone is combined with Benzocaine.Approved
Benzoyl peroxideThe risk or severity of adverse effects can be increased when Benzoyl peroxide is combined with Dapsone.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Dapsone.Investigational
BoceprevirThe metabolism of Dapsone can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Dapsone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dapsone can be decreased when it is combined with Bosentan.Approved, Investigational
ButalbitalThe risk or severity of adverse effects can be increased when Dapsone is combined with Butalbital.Approved, Illicit
CapecitabineThe metabolism of Dapsone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Dapsone can be increased when combined with Carbamazepine.Approved, Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Dapsone is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dapsone can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Dapsone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Dapsone.Approved, Vet Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Dapsone.Experimental
ChlorproguanilThe risk or severity of adverse effects can be increased when Chlorproguanil is combined with Dapsone.Investigational
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dapsone.Approved, Vet Approved
CholecalciferolThe metabolism of Dapsone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Dapsone can be decreased when combined with Cimetidine.Approved
CitalopramThe metabolism of Dapsone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Dapsone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dapsone can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Dapsone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Dapsone can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Dapsone can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Dapsone can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Dapsone can be decreased when combined with Crizotinib.Approved
Cycloguanil embonateThe risk or severity of adverse effects can be increased when Cycloguanil embonate is combined with Dapsone.Experimental
CyclosporineThe metabolism of Dapsone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Dapsone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Dapsone can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Dapsone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dapsone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dapsone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dapsone can be decreased when combined with Delavirdine.Approved
DihydroergotamineThe metabolism of Dapsone can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Dapsone can be decreased when combined with Diltiazem.Approved
DosulepinThe metabolism of Dapsone can be decreased when combined with Dosulepin.Approved
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Dapsone.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dapsone can be decreased when combined with Dronedarone.Approved
EfavirenzThe metabolism of Dapsone can be decreased when combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Dapsone can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Dapsone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Dapsone can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Dapsone can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe metabolism of Dapsone can be decreased when combined with Etravirine.Approved
FelodipineThe metabolism of Dapsone can be decreased when combined with Felodipine.Approved, Investigational
FloxuridineThe metabolism of Dapsone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Dapsone can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Dapsone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Dapsone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Dapsone.Approved
FlutamideThe risk or severity of adverse effects can be increased when Dapsone is combined with Flutamide.Approved
FluvastatinThe metabolism of Dapsone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Dapsone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dapsone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dapsone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dapsone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Dapsone can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Dapsone can be decreased when combined with Gemfibrozil.Approved
HalofantrineThe risk or severity of adverse effects can be increased when Halofantrine is combined with Dapsone.Approved
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone.Approved
IdelalisibThe serum concentration of Dapsone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Dapsone can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Dapsone can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Dapsone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Dapsone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsomethepteneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isometheptene.Approved
IsoniazidThe metabolism of Dapsone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Mononitrate.Approved
IsradipineThe metabolism of Dapsone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dapsone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dapsone can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Dapsone can be decreased when combined with Ketoconazole.Approved, Investigational
LapatinibThe metabolism of Dapsone can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Dapsone can be decreased when combined with Leflunomide.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Dapsone is combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Dapsone can be decreased when combined with Lobeglitazone.Approved
LopinavirThe metabolism of Dapsone can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Dapsone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Dapsone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Dapsone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dapsone can be increased when it is combined with Lumacaftor.Approved
MafenideThe risk or severity of adverse effects can be increased when Dapsone is combined with Mafenide.Approved, Vet Approved
ManidipineThe metabolism of Dapsone can be decreased when combined with Manidipine.Approved
MefloquineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Dapsone.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Dapsone.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Dapsone.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Dapsone.Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Dapsone is combined with Metoclopramide.Approved, Investigational
MidostaurinThe metabolism of Dapsone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Dapsone can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Dapsone can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone.Investigational
MoclobemideThe metabolism of Dapsone can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Dapsone can be decreased when combined with Modafinil.Approved, Investigational
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Dapsone.Approved, Withdrawn
NefazodoneThe metabolism of Dapsone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dapsone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dapsone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dapsone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Dapsone can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Dapsone can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Dapsone can be decreased when combined with Nilotinib.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dapsone.Approved
NitrofurantoinThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitrofurantoin.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitroprusside.Approved
OlaparibThe metabolism of Dapsone can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Dapsone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Dapsone can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Dapsone can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Dapsone can be decreased when combined with Pantoprazole.Approved
PentobarbitalThe metabolism of Dapsone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Dapsone.Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Dapsone.Approved
PhenazopyridineThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenazopyridine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenobarbital.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dapsone.Approved
PioglitazoneThe metabolism of Dapsone can be decreased when combined with Pioglitazone.Approved, Investigational
PosaconazoleThe metabolism of Dapsone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrilocaineThe risk or severity of adverse effects can be increased when Dapsone is combined with Prilocaine.Approved
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Dapsone.Approved
PrimidoneThe metabolism of Dapsone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Dapsone can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Dapsone.Approved, Vet Approved
ProguanilThe risk or severity of adverse effects can be increased when Proguanil is combined with Dapsone.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Dapsone.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Dapsone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Dapsone.Vet Approved
PyrimethamineThe risk or severity of adverse effects can be increased when Pyrimethamine is combined with Dapsone.Approved, Vet Approved
PyronaridineThe risk or severity of adverse effects can be increased when Pyronaridine is combined with Dapsone.Investigational
QuinacrineThe risk or severity of adverse effects can be increased when Quinacrine is combined with Dapsone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dapsone.Approved
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Dapsone.Approved
RabeprazoleThe metabolism of Dapsone can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Dapsone.Experimental
RanolazineThe metabolism of Dapsone can be decreased when combined with Ranolazine.Approved, Investigational
RitonavirThe metabolism of Dapsone can be decreased when combined with Ritonavir.Approved, Investigational
RosiglitazoneThe metabolism of Dapsone can be decreased when combined with Rosiglitazone.Approved, Investigational
SaquinavirThe metabolism of Dapsone can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Dapsone can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Dapsone can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Dapsone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dapsone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dapsone can be increased when it is combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Dapsone.Experimental
Sodium NitriteThe risk or severity of adverse effects can be increased when Dapsone is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Dapsone can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Dapsone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dapsone can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe risk or severity of adverse effects can be increased when Dapsone is combined with Sulfadiazine.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Dapsone.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Dapsone is combined with Sulfamethoxazole.Approved
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Dapsone.Approved, Withdrawn
SulfisoxazoleThe metabolism of Dapsone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
tafenoquineThe risk or severity of adverse effects can be increased when tafenoquine is combined with Dapsone.Investigational
TamoxifenThe metabolism of Dapsone can be decreased when combined with Tamoxifen.Approved
TelaprevirThe metabolism of Dapsone can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Dapsone can be decreased when combined with Telithromycin.Approved
TeriflunomideThe metabolism of Dapsone can be decreased when combined with Teriflunomide.Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Dapsone.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Dapsone.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dapsone.Withdrawn
TicagrelorThe metabolism of Dapsone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Dapsone can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Dapsone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Dapsone can be decreased when combined with Tolbutamide.Approved
TopiramateThe metabolism of Dapsone can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Dapsone can be decreased when combined with Topiroxostat.Approved
TranylcypromineThe metabolism of Dapsone can be decreased when combined with Tranylcypromine.Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Dapsone.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Dapsone.Approved, Vet Approved
Valproic AcidThe metabolism of Dapsone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Dapsone can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Dapsone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Dapsone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Dapsone can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Dapsone can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Dapsone can be decreased when combined with Ziprasidone.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Dapsone is combined with Zopiclone.Approved
ZucapsaicinThe metabolism of Dapsone can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Weijiard, J.and Messerly, J.P.; U.S. Patent 2,385,899; October 2,1945; assigned to Merck & Co., Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB14395
KEGG Drug
D00592
KEGG Compound
C07666
PubChem Compound
2955
PubChem Substance
46505300
ChemSpider
2849
BindingDB
50029764
ChEBI
4325
ChEMBL
CHEMBL1043
Therapeutic Targets Database
DAP000637
PharmGKB
PA449211
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dapsone
ATC Codes
D10AX05 — DapsoneJ04BA02 — Dapsone
AHFS Codes
  • 08:16.92 — Miscellaneous Antimycobacterials
  • 84:04.92 — Miscellaneous Local Anti-infectives
FDA label
Download (515 KB)
MSDS
Download (53.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAcne Vulgaris1
1CompletedBasic ScienceLinear IgA Bullous Dermatosis / Methaemoglobinaemia1
1CompletedTreatmentAcne Vulgaris2
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Bacterial / Mycoses1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii2
1WithdrawnNot AvailableAcne Vulgaris1
1WithdrawnTreatmentAcne Vulgaris1
2CompletedTreatmentChronic Lung Diseases / Pulmonary Fibrosis / Sarcoidosis1
2RecruitingTreatmentCutaneous Polyarteritis Nodosa / Henoch-Schönlein Purpura / IgA Vasculitis / Primary Cutaneous Vasculitis1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Rash1
2TerminatedTreatmentPemphigus Vulgaris (PV)1
2, 3Unknown StatusPreventionCerebral Stroke / Cerebrovascular Accident, Acute / Cerebrovascular Stroke / Stroke, Acute / Strokes1
3CompletedTreatmentAcne1
3CompletedTreatmentAcne Vulgaris4
3CompletedTreatmentCetuximab-induced Papulopustular (Acneiform) Rash Who Have / Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii4
3RecruitingTreatmentAdult Immune Thrombocytopenia (ITP) / Dapsone1
3TerminatedTreatmentPlasmodium Infections1
4CompletedTreatmentAcne Vulgaris7
4CompletedTreatmentBMI >30 kg/m2 / Hansen's Disease / Tuberculosis1
4CompletedTreatmentHansen's Disease1
4RecruitingTreatmentAcne1
4RecruitingTreatmentAcne Vulgaris1
4RecruitingTreatmentAcne / Allergic Cutaneous Vasculitis / Bullous Skin Diseases / Hansen's Disease / Pneumonia, Pneumocystis / Psoriasis / Sterile Pustulosis / Urticarias1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableCompletedNot AvailableChronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Methaemoglobinaemia / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Nonmalignant Neoplasm1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii2
Not AvailableNot Yet RecruitingTreatmentLichen Simples Chronicus and Prurigo1
Not AvailableRecruitingOtherHealthy Volunteers1
Not AvailableUnknown StatusTreatmentBullous dermatitis herpetiformis1

Pharmacoeconomics

Manufacturers
  • Jacobus pharmaceutical co
Packagers
Dosage forms
FormRouteStrength
GelTopical5 %
GelTopical50 mg/g
GelTopical75 mg/g
TabletOral100 mg
TabletOral100 mg/1
TabletOral25 mg/1
Prices
Unit descriptionCostUnit
Dapsone 30 100 mg tablet Box42.99USD box
Dapsone 30 25 mg tablet Box35.99USD box
Aczone 5% gel5.52USD g
Dapsone powder5.38USD g
Dapsone 100 mg tablet0.86USD tablet
Dapsone 25 mg tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2265461No2004-11-302017-09-10Canada
US6060085No1996-09-112016-09-11Us
US5863560No1996-09-112016-09-11Us
US6620435No1996-09-112016-09-11Us
US9161926No2013-11-182033-11-18Us
US9517219No2013-11-182033-11-18Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)175.5 °CNot Available
water solubility380 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.97HANSCH,C ET AL. (1995)
logS-2.82ADME Research, USCD
pKa2.41PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.284 mg/mLALOGPS
logP1.19ALOGPS
logP1.27ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)2.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.18 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity68.99 m3·mol-1ChemAxon
Polarizability25.05 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8476
Blood Brain Barrier+0.9705
Caco-2 permeable+0.5879
P-glycoprotein substrateNon-substrate0.8699
P-glycoprotein inhibitor INon-inhibitor0.9311
P-glycoprotein inhibitor IINon-inhibitor0.9572
Renal organic cation transporterNon-inhibitor0.8739
CYP450 2C9 substrateNon-substrate0.7416
CYP450 2D6 substrateSubstrate0.86
CYP450 3A4 substrateNon-substrate0.7175
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8955
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.6127
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.556
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.5795
BiodegradationNot ready biodegradable0.9778
Rat acute toxicity2.3635 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9859
hERG inhibition (predictor II)Non-inhibitor0.864
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.27 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-052g-8930000000-c51783649020dadfb20f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0190000000-7de0f1aeb77cf9b122f5
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0290000000-f1e61c46f1720875a177
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-0920000000-ed66532a51b7d047462a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4l-3900000000-a1f636a2e557bc9b69a5
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-052f-9800000000-3557ad8246dc0a0aa05c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-5910000000-0c8eb03605a271970f1d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-0590000000-a23b099ad5d2d3cd716d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-1920000000-0260de715fec538fe8bb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-5900000000-6ba41fa3598abafdb242
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-9600000000-d2fe4c5ba425499ba98c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-9400000000-e29e2bdac763fc5e250b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066u-9200000000-71494cee2792628e6a0c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9000000000-38433ad894a5e08f6ee0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9000000000-e4782e47ceb05d1ffbda
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9000000000-4ab9019e60b1718d1d29
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-0190000000-d7cf0928be57fafd7ea4
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-1930000000-09cf0e392eeef139f2b1
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4l-8900000000-5da3a6d058cb14fc8300
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052f-9500000000-caa724a9dddce38f915b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05mo-9200000000-dc177a76811dcf904424
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0a4i-0900000000-b8af4ee792a585775315
MS/MS Spectrum - , positiveLC-MS/MSsplash10-052b-1890000000-6210a606dbc1cafdcb2a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-5901100000-901603cf86087b4a4abb
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonyl compounds
Direct Parent
Benzenesulfonyl compounds
Alternative Parents
Aniline and substituted anilines / Sulfones / Primary amines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Benzenesulfonyl group / Aniline or substituted anilines / Sulfonyl / Sulfone / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Primary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfone, substituted aniline (CHEBI:4325)

Targets

Kind
Protein
Organism
Mycobacterium leprae (strain TN)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Has very low affinity for the DHPS substrate 6-hydroxymethyl-7,8-dihydropterin-pyrophosphate, but can bind the inhibitor dapsone. Seems to lack dihydropteroate synthase activity, and does probably not function in folate metabolism (By similarity).
Specific Function
Dihydropteroate synthase activity
Gene Name
folP2
Uniprot ID
P0C0X2
Uniprot Name
Inactive dihydropteroate synthase 2
Molecular Weight
30850.89 Da
References
  1. Gillis TP, Williams DL: Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae. Indian J Lepr. 1999 Jan-Mar;71(1):11-8. [PubMed:10439322]
  2. Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7. [PubMed:10817704]
  3. Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. doi: 10.1111/j.1574-6968.2008.01302.x. Epub 2008 Aug 1. [PubMed:18680522]
Kind
Protein
Organism
Mycobacterium leprae (strain TN)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate, the immediate precursor of folate derivatives.
Gene Name
folP1
Uniprot ID
P0C0X1
Uniprot Name
Dihydropteroate synthase
Molecular Weight
29447.355 Da
References
  1. Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V: Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis. 2006 Jan 15;42(2):238-41. Epub 2005 Dec 12. [PubMed:16355335]
  2. Lee SB, Kim SK, Kang TJ, Chae GT, Chun JH, Shin HK, Kim JP, Ko YH, Kim NH: The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Ann Trop Med Parasitol. 2001 Jun;95(4):429-32. [PubMed:11454253]
  3. Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7. [PubMed:10817704]
  4. Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. doi: 10.1111/j.1574-6968.2008.01302.x. Epub 2008 Aug 1. [PubMed:18680522]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Winter HR, Wang Y, Unadkat JD: CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8. [PubMed:10901692]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Trimethylamine monooxygenase activity
Specific Function
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an impor...
Gene Name
FMO3
Uniprot ID
P31513
Uniprot Name
Dimethylaniline monooxygenase [N-oxide-forming] 3
Molecular Weight
60032.975 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Arylamine n-acetyltransferase activity
Specific Function
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivat...
Gene Name
NAT2
Uniprot ID
P11245
Uniprot Name
Arylamine N-acetyltransferase 2
Molecular Weight
33542.235 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:21